Revolutionary lung
cancer mortality
reduction of >25%

It’s safe to say that early detection of lung cancer would impact the lives of millions. Several scientific leaders therefore decided to try and develop a lung cancer screening protocol that would greatly improve detection rates and thereby increase the chances of survival. The NELSON protocol is the only randomised lung cancer screening trial in which pulmonary nodule management is based on volumetry and volumetric doubling time.

The protocol will lead to early detection and early treatment of lung cancer, which will translate to a lung cancer related mortality reduction of:

- 26% mortality reduction in males

- 39% mortality reduction in females

- 1.6% false positives

Potential Impact of NELSON

Lung cancer is the leading cause of cancer-related deaths in the world. Annually, lung cancer claims more lives than colon, prostate, ovarian and breast cancers combined. Lung cancer is typically very difficult to diagnose: it doesn’t cause signs and symptoms in its earliest stages. When a notable cough is detected, the disease is often already at a point of no return. Combined with the extremely rapid metastasis that characterizes lung cancer, the chances of survival are slim for the 1.9 million people world wide that are diagnosed with lung cancer every year.

After 20 years of extensive research, the team behind the NELSON study recently presented its much-anticipated results. It has delivered on its promise to detect lung cancer in an early stage, significantly reducing lung cancer associated mortality by 26% in men and by 39% in women, whilst simultaneously leading to a relatively low amount of false-positive referrals (1.6%). Worldwide implementation of the lung cancer screening protocol would save the lives of millions of people. Numerous governments have therefore already started the first steps of implementation of lung cancer screening.


iDNA, the Institute for DiagNostic Accuracy, is the premier organization supporting successful and effective implementation of lung cancer screening. iDNA was launched by members of the NELSON group and is backed by numerous scientific experts and business leaders. We are established in the Netherlands, where the NELSON protocol was developed. Our mission is to reduce the burden of lung cancer by assisting health care organizations and governments in successfully and effectively implementing the NELSON protocol.

iDNA diagnostic game-changer


We would be honoured to support you in setting up a lung cancer screening programme in your country, region or hospital. Please enter your request on the right, or send a direct email to if you have any questions.